Virtus ETF Advisers LLC C4 Therapeutics, Inc. Transaction History

Virtus ETF Advisers LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.1 - $9.02 $14,731 - $42,863	-4,752 Reduced 27.79%	12,350 $38,000
Q4 2022 Feb 14, 2023	SELL	$5.42 - $10.24 $11,940 - $22,558	-2,203 Reduced 11.41%	17,102 $100,000
Q3 2022 Nov 14, 2022	BUY	$8.03 - $12.77 $1,092 - $1,736	136 Added 0.71%	19,305 $169,000
Q2 2022 Aug 12, 2022	BUY	$5.06 - $26.46 $70,303 - $367,635	13,894 Added 263.39%	19,169 $145,000
Q1 2022 May 16, 2022	SELL	$19.99 - $33.23 $6,276 - $10,434	-314 Reduced 5.62%	5,275 $128,000
Q4 2021 Feb 14, 2022	BUY	$29.39 - $46.86 $16,046 - $25,585	546 Added 10.83%	5,589 $180,000
Q3 2021 Nov 15, 2021	SELL	$35.91 - $50.5 $9,659 - $13,584	-269 Reduced 5.06%	5,043 $225,000
Q2 2021 Aug 10, 2021	BUY	$30.39 - $42.18 $161,431 - $224,060	5,312 New	5,312 $201,000

129

63.5M

670K

54.8K

Ticker CCCC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,913,800
Market Cap $164M
Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...

Get notified when there are updates to the investment portfolio of Virtus ETF Advisers LLC, based on Form 13F filings with the SEC.

Stay updated on Virtus ETF Advisers LLC with notifications on news.